RxDoctor Payments Data

Mohammed Algodi, MD

Cardiovascular Disease · Bronx, NYNPI 1760839450

Payments from drug & device makers

$4,764in general payments, 2019–2025

Across 186 payments — averaging $25.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$646
  • Novartis$570
  • Pfizer$482
  • Amgen$463
  • Boehringer Ingelheim$450
  • Shockwave Medical, Inc$405
  • plus $2K from 13 others

What the payments were for

  • Food & beverage$4,51195%
  • Education$2535%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,764 in reported general payments places this provider in the 70th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Medicare billing

Part B allowed, 2024
$83,516
Medicare patients
241
Services billed
610

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban90$86,716
EntrestoSacubitril/Valsartan66$70,836
FarxigaDapagliflozin Propanediol47$48,732
JardianceEmpagliflozin32$31,113
Nifedipine ErNifedipine189$4,276
Metoprolol Succinate295$3,845
Atorvastatin Calcium265$2,615
Losartan Potassium240$1,890
Amlodipine Besylate213$1,260
Ranolazine ErRanolazine30$1,231
Ezetimibe49$1,226
Chlorthalidone83$895
Nitroglycerin17$571
Valsartan20$518
Hydralazine Hcl39$496

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$482$86,71690 claims
NovartisEntresto$570$70,83666 claims
AstraZenecaFarxiga$324$48,73247 claims
Boehringer IngelheimJardiance$450$31,11332 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,302 cardiovascular disease providers in New York.

Other cardiovascular disease in Bronx

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →